Regulus Therapeutics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Regulus Therapeutics reports Q1 2025 results, highlighting ongoing losses and liquidity concerns despite a pending acquisition by Novartis.
10-Q: Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Update
Regulus Therapeutics Inc. has released its financial results for the third quarter of 2024, alongside updates on its clinical programs, particularly RGLS8429 for ADPKD.
10-Q: Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Regulus Therapeutics reported a net loss of $11.0 million for the second quarter of 2024, while highlighting progress in its RGLS8429 clinical trial for ADPKD.
10-Q: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Regulus Therapeutics reported a net loss of $8.5 million for the first quarter of 2024, while highlighting progress in its RGLS8429 clinical trial for ADPKD.